Company profile

Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd.—— China's leading GMP peptide API enterprise, Shanghai high-tech enterprise

    Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd.(ankebio Wholly owned subsidiary), founded in 2001, is a research, development, production and sales of various GMP peptide raw materials and drugs based high-tech enterprises.

    The company has the international advanced level of experimental and production facilities: automatic peptide synthesis system, separation and purification system, freeze-drying system and other equipment. On the basis of introducing, digesting and absorbing the most advanced peptide synthesis and production technology in the world, we have established a domestic leading high-tech platform for large-scale research and development of active small molecular peptide drugs and precursors, and independently developed our unique solid-phase synthesis process route suitable for industrial production, providing peptide preparation enterprises at home and abroad with extremely high price advantage and high-quality peptide raw materials Medicine. At present, there are more than 40 polypeptide APIs which have been listed at home and abroad or are in clinical stage. The product distribution and output are in the leading position in China. The company provides high-quality peptide products, peptide purification services, peptide synthesis reagents and technical consulting services for the majority of users.

    The tenet of the company is: on the basis of introducing, digesting and absorbing the most advanced peptide drug production technology in the world, relying on the most advanced bioengineering technology and information at home and abroad, continuously absorb the latest peptide Pharmaceuticals new technology at home and abroad, strive to improve the technical level, enhance the scientific research strength, and form the scientific management concept, business philosophy and customer-oriented service concept The core of the corporate culture is honesty and pragmatism, pioneering spirit, innovation and solidarity. Efforts to improve product quality, reduce production costs, and continue to provide customers with high-quality, low-cost peptide raw materials. In line with the service concept of common growth and sharing success with customers, we are committed to building the company into the largest, most advanced and most influential professional peptide Pharmaceuticals company in China.

    Since 2007, the company has been rated as a national high-tech enterprise, and is a "small giant of science and technology" in Putuo District. Seven new varieties of somatostatin, octreotide acetate, salmon calcitonin, thymopentin, leuprorelin, oxytocin, thymopentin were awarded the title of Shanghai high-tech achievements transformation project; somatostatin was awarded the title of Shanghai key new product, and was listed as the innovation fund project for small and medium enterprises of the Ministry of science and technology; octreotide acetate was listed as the national Torch Program project; thymus method was selected as the national Torch Program project It is newly listed as the innovation fund project of small and medium-sized enterprises of the Ministry of science and technology of the people's Republic of China. The company has also been rated as the top 50 pharmaceutical industry with the most development potential in China.

    The company attaches great importance to the protection of intellectual property rights, and has applied for more than ten Chinese invention patents and one American invention patent for thymopentin, leuprorelin, terlipressin, somatostatin, octreotide, oxytocin, thymus 28 peptide and bivalirudin. Octreotide acetate won the first prize of the 18th excellent invention award of Shanghai, somatostatin won the second prize of the 19th excellent invention of Shanghai, oxytocin won the second prize of the 20th excellent invention of Shanghai, and Mr. Zhou Yiming, general manager of the company, was awarded the top 20 outstanding inventions of Shanghai for 20 years. He is a young and middle-aged expert in Shanghai and a member of Shanghai expert database.

    The company has moved to a new large GMP peptide API production base located in Qingpu District, Shanghai. The base aims at the new requirements of GMP hardware at home and abroad, and constructs from a high starting point. With strict and comprehensive GMP management, the company realizes strict control of product quality. The company's five new varieties of thymopentin, octreotide acetate, somatostatin, salmon calcitonin and Thymosin have passed the GMP certification of the State Food and drug administration. At present, the company is the only polypeptide API supplier that has passed the GMP certification of the five varieties. In recent years, the company's oxytocin products have obtained the European CEP certificate and entered the European market.

     At present, the company has achieved batch production of 6 kg grade, with annual production and sales of more than 300 kg of various polypeptide APIs with high purity (above 99%), with sales revenue of nearly 100 million yuan, ranking the first in domestic market share for many consecutive years, and has the production capacity of polypeptide API with an annual output of more than 500 kg.